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Adeno-associated virus (AAV) integrates its genomic DNA into a defined region of human chromosome 19 (AAVS1). The
specificity of integration is dependent on the presence of the inverted terminal repeats (ITR) and on expression of the rep gene.
To develop vectors capable of targeting the insertion of a selected DNA sequence into a specific location of human chromosome,
we determined whether the rep gene can mediate site-specific integration when cloned outside of an ITR-flanked transgene
cassette. HeLa and Huh-7 cells were transfected with a plasmid containing the rep gene, as well as the green fluorescent protein
(GFP) and neomycin (neo) resistance gene inserted between the ITRs of AAV. Southern blot analysis of individual clones detected
Rep-mediated site-specific integration of the ITR-flanked DNA in 25% and 12% of the HeLa and Huh-7 clones, respectively. The
localization of the GFP-Neo sequence on chromosome 19 also was confirmed by fluorescent in situ hybridization analysis of the
transfected HeLa clones. Sequence analysis of the ITR–AAVS1 junction of one of the transfected Huh-7 clones indicated that the
insertion of the ITR DNA fragment had occurred at nucleotide 1003. These results have implications for the development of
AAV-derived vectors capable of directing the site-specific integration of a gene of interest. © 1998 Academic Press
INTRODUCTION
Adeno-associated virus (AAV) has gained recent inter-
est as a viral vector for gene therapy on the basis of its
lack of pathogenicity and its unique capacity of prefer-
entially integrating its viral DNA within a defined region
of the cellular genome. AAV is a human parvovirus that
usually requires adenovirus (Ad) or herpesvirus as a
helper to replicate efficiently (Berns, 1996). In the ab-
sence of helper virus, the AAV genome integrates into
host-cell genomic DNA and is maintained as a latent
provirus. Analysis of flanking sequences from latently
infected cells has revealed integration of the AAV ge-
nome into a specific locus in 60–70% of cases. The
integration locus (AAVS1) has been sequenced and lo-
calized to human chromosome 19q13.3-qter (Giraud et
al., 1994; Kotin et al., 1990, 1992; Samulski et al., 1991).
Other, less-frequent integration sites have been identi-
fied in the long arm of chromosome 17 in latently infected
HeLa cells (Waltz and Shlehofer, 1992).
The AAV DNA genome is a linear single-stranded DNA
molecule of ;4700 nucleotides. The AAV genome has
one copy of the 145-nucleotide-long inverted terminal
repeat (ITR) located at each end. The ITRs are needed for
viral integration, rescue from the host genome, and en-
capsidation of viral nucleic acids into mature virions
(Samulski, 1993; Weitzman et al., 1994). Inserted between
the ITRs of AAV is a unique region of ;4470 nucleotides
that contains two main open reading frames (ORFs). The
right ORF, Cap, encodes the viral structural proteins. The
left ORF of the AAV genome encodes the rep gene. Two
promoters located at map positions 5 and 19 (promoters
P5 and P19, respectively) control the expression of the
four polypeptides derived from this ORF. Rep proteins
Rep78 and Rep68 are produced from the p5 promoted
transcripts, and Rep polypeptides Rep52 and Rep40 are
synthesized from the p19 promoted transcripts (Srivas-
tava et al., 1983).
The mechanism of AAV integration is not yet fully
understood; however, a model was recently proposed in
which the insertion of the AAV genome into chromosome
19 is promoted by the Rep polypeptides and is accom-
panied by limited DNA synthesis of the AAVS1 site (Lin-
den et al., 1996). This model is based in part on the
observation that the larger polypeptides Rep78 and
Rep68 have been shown to possess ATP-dependent he-
licase and strand-specific endonuclease activities (Im
and Muzyczka, 1990, 1992). In addition, these proteins
can bind DNA in a sequence-specific manner (Ashktorab
and Srivastava, 1989; Im and Muzyczka, 1989). A Rep
binding site has been identified in both the ITR of AAV
and the AAVS1 site, and it has been shown that the Rep
polypeptides can interact in vitro with these sequences
and promote their nicking and replication (Snyder et al.,
1990; Urcelay et al., 1995). Furthermore, it has been
demonstrated that the Rep78 and Rep68 polypeptides
can individually mediate complex formation between the
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ITR of AAV and the AAVS1 in vitro (Weitzman et al., 1994).
In agreement with the involvement of the Rep polypep-
tides and possibly of other cellular factors in the inter-
action with the AAV terminal repeats and with AAVS1, the
Rep78 protein has been shown to form in vitro multimeric
complexes (Hermonat and Batchu, 1997) and to self-
associate in the presence of AAV ITRs (Smith et al.,
1997). This model of Rep-mediated targeted insertion
has been confirmed, at least in part, by experimental
evidence indicating that AAV terminal repeats are the
required substrate for viral integration in conjunction
with the host cellular recombination machinery (Yang et
al., 1997) and that expression of Rep proteins is neces-
sary for targeted insertion into the AAVS1 locus proteins
(Balague´ et al., 1997; Kearns et al., 1996; Shelling and
Smith, 1994). In addition, it has been shown that expres-
sion of only Rep78 or Rep68 is sufficient to obtain highly
efficient integration into the AAVS1 site (Lamartina et al.,
1998; Surosky et al., 1997).
The main limitation of AAV for gene therapy is consti-
tuted by the packaging limit of the AAV virion, which
cannot exceed 4.5 kb. Thus, most of the AAV-derived
vectors have been generated by deleting the Rep and
Cap genes and replacing them with the gene to be
delivered. These vectors can persist for a prolonged
period of time as episomal forms or they can integrate
randomly, thus supporting the role of the Rep polypep-
tides in targeting to chromosome 19 (Afione et al., 1996;
Fisher et al., 1997; Flotte et al., 1994; Hermonat and
Muzyczka; 1984; Kaplitt et al., 1994; Kearns et al., 1996;
Kessler et al., 1996; Koebler et al., 1997; LaFace et al.,
1988; Lebkowski et al., 1996; McLaughlin et al., 1988;
Philip et al., 1994; Reed Clark et al., 1997; Russel et al.,
1994; Tratschin et al., 1985; Xiao et al., 1996).
In an effort to develop a reliable delivery system that
will allow us to achieve targeted integration of foreign
DNA, we examined the contribution of AAV rep gene on
the efficiency of site-specific integration of transfected
plasmids. We analyzed the efficiency of site-specific in-
tegration in transfected cells of constructs carrying the
rep gene located outside of the AAV ITRs and compared
it with that of a similar plasmid lacking the rep gene. The
results obtained indicate that integration of a specific
DNA fragment into the AAVS1 site occurs at a significant
frequency and in different cell types.
RESULTS
Construction of AAV-derived plasmids
To determine whether the rep gene of AAV can be
used as a means of directing the site-specific integration
of a gene of interest into the DNA of target cells, plasmid
pITR(GFP-Neo)P5Rep and the control plasmid pITR(GFP-
Neo) were constructed (Fig. 1). In both plasmids, the neo
gene and the green fluorescent protein (GFP) gene were
inserted between the 59 and 39 ITRs of AAV. In addition,
in plasmid pITR(GFP-Neo)P5Rep, the rep gene under the
transcriptional control of AAV P5 and P19 promoters was
cloned outside the two ITRs but next to the 39 terminal
repeat. To verify that the expression of Rep52 and Rep40
is not required for site-specific integration, plasmid pITR-
(GFP-Neo)P5Rep78/68 was also constructed, in which
the ATG located downstream of promoter P19 had been
mutated.
The functionality of these plasmids in determining the
replication of the ITR-flanked DNA was assessed by
transfection in Ad5-infected 293 cells. As control, pITR-
(GFP-Neo) was cotransfected with an helper plasmid,
pAd/AAV. This construct encodes the Rep and Cap poly-
peptides but is incapable of replicating itself due to the
absence of AAV ITRs (McLaughlin et al., 1988; Samulski
et al., 1989). The replication pattern of these plasmids
was compared with that of plasmid pSub201. Low-mo-
lecular-weight DNA was isolated 48 h posttransfection
FIG. 1. Schematic representation of the plasmid constructs used in the study. Plasmids pITR(GFP-Neo), pITR(GFP-Neo)P5Rep, and pITR(GFP-
Neo)P5Rep78/68 contain an GFP and neomycin expression cassette flanked by AAV ITRs. The immediate early CMV promoter and SV40 early
promoters as well as the bovine growth hormone (gh) and SV40 polyadenylation signals are indicated. Constructs pITR(GFP-Neo)P5Rep and
pITR(GFP-Neo)P5Rep78/68 also contain the rep gene under the transcriptional control of P5 and P19 promoters located downstream of the ITR-flanked
DNA element. Plasmid pITR(GFP-Neo)P5Rep78/68 encodes only the two larger Rep polypeptides. Relevant restriction site is indicated. The plasmids
were constructed as described in Materials and Methods.
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and fractionated on an agarose gel after digestion with
restriction enzyme DpnI to degrade unreplicated input
plasmid DNA. DpnI distinguishes between the newly
replicated DNA and input plasmid DNA based on resis-
tance to digestion due to the loss of methylation (Wobbe
et al., 1985). The digested DNA was then subjected to
Southern blot analysis using a probe specific for the ITR
sequence (Fig. 2). Plasmid pSub201 produced DpnI-re-
sistant bands of ;4.5 and ;9.0 kb corresponding to the
monomeric and dimeric forms of the AAV genome, indi-
cating that viral genome had undergone successful res-
cue and replication (Fig. 2, lane 1). In the absence of the
AAV helper, plasmid pITR(GFP-Neo) was DpnI sensitive,
and no bands could be detected with the ITR-specific
probe (Fig. 2, lane 2). In contrast, when transfected with
the helper plasmids pAd/AAV, a band of 3.5 kb resistant
to DpnI digestion was apparent. This band corresponds
to the monomeric GFP-Neo fragment inserted between
the ITRs of AAV, thus indicating that the ITR DNA frag-
ment had undergone successful rescue and replication
(Fig. 2, lane 3). Similarly, constructs pITR(GFP-Neo)P5Rep
and pITR(GFP-Neo)P5Rep78/68 transfected alone dis-
played the same 3.5-kb DpnI-resistant band that hybrid-
ized to the ITR-specific probe (Fig. 2, lanes 4 and 5).
Thus, the results indicate that the plasmids contain func-
tional ITR sequences and that in agreement with pub-
lished data (Samulski et al., 1989), the Rep polypeptides
are fully capable of determining the rescue and replica-
tion of the ITR DNA segment when expressed outside of
the ITR context.
Site-specific integration of AAV-derived constructs
The efficiency of site-specific integration of pITR(GFP-
Neo)P5Rep and pITR(GFP-Neo)P5Rep78/68 was com-
pared with that of pITR(GFP-Neo) by transfection of HeLa
cells. In addition, in view of the fact that liver-specific
gene transfer has received a great deal of attention
because of the large biosynthetic capacity of this organ
and because many genetic diseases result from the
absence or deficiency of a hepatocyte-derived gene
product (Ledley, 1993), the human hepatoma cell line
Huh-7 was also used to assess the efficiency of targeted
integration of the AAV-derived plasmids.
Neomycin-resistant clones were isolated and expanded,
and high-molecular-weight DNA was extracted and sub-
jected to Southern blot analysis. The rearrangement of the
AAVS1 site resulting from the integration of the transfected
plasmid was verified using AAVS1- and neo-specific
probes. The hybridization pattern of selected clones was
compared with that of mock-transfected cells. Site-specific
integration of the transfected plasmid was scored when the
two following conditions were met: (1) The hybridization
pattern of the genomic DNA using the AAVS1 probe was
different from that of the mock-transfected cells DNA in that
it contains an additional restriction fragment recognized by
the AAVS1 probe. (2) The same additional fragment re-
vealed with the genomic probe was detected with the
neo-specific probe.
As shown in Figure 3, in 3 of 25 (12%) Huh-7 selected
clones that had been transfected with plasmid pITR(GFP-
Neo)P5Rep, the AAVS1 probe hybridized to a fragment
ranging in size of 4.5–10 kb that was not detected in the
mock-transfected Huh-7 genomic DNA (Fig. 3A, compare
lanes 3, 7, and 12 with lane 1). The same band was
hybridized by the neo-specific probe, indicating that in-
tegration of the ITR-flanked DNA into chromosome 19
also had occurred in these cells (Fig. 3B, lanes 3, 7, and
12). The site-specific integration of the ITR-flanked DNA
was revealed with both the neo- and GFP-specific
probes, indicating that both markers had integrated into
the AAVS1 site (data not shown).
The summary of results obtained in the transfection of
both HeLa and Huh-7 cells are shown in Table 1. No
site-specific integration was detected in 39 selected
HeLa cell clones that had been transfected with plasmid
pITR(GFP-Neo). In contrast, targeted integration in the
AAVS1 site was detected in 8 of 32 (25%) clones trans-
fected with plasmid pITR(GFP-Neo)P5Rep and in 7 of 38
FIG. 2. Southern blot analysis of rescue of AAV genome and of
recombinant plasmids from transfected constructs in human 293 cells.
Five micrograms of each of the recombinant plasmids were transfected
in Ad5-infected 293 cells. Low-molecular-weight DNA was isolated 40 h
posttransfection using published protocols (Hirt, 1967), digested exten-
sively with DpnI, and analyzed on Southern blots using a 32P-labeled
probe specific for the ITR sequence. Rescue and replication of the
wild-type AAV from plasmid pSub201 (lane 1) is readily apparent.
Similarly, rescue of the ITR-flanked DNA fragment from plasmids
pITR(GFP-Neo)P5Rep (lane 4) and pITR(GFP-Neo)P5Rep78/68 (lane 5) is
readily apparent. No rescue and replication occurs on transfection of
plasmid pITR(GFP-Neo) (lane 2) unless it is cotransfected with helper
plasmids pAd/AAV (lane 3).
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(18%) clones transfected with pITR(GFP-Neo)P5Rep78/
68. Transfection of Huh-7 cells with plasmid pITR(GFP-
Neo)P5Rep78/68 resulted in site-specific integration of
the ITR-flanked DNA into 2 of 26 clones (7%).
The selectivity of integration of the ITR-flanked DNA
fragment into the AAVS1 site was assessed by hybrid-
ization of the BamHI-digested genomic DNA of the trans-
fected clones with a probe specific for the rep gene. No
band could be hybridized by the rep-specific probe, and
no Rep activity could be detected by performing rescue
FIG. 3. Southern blot analysis of Huh-7 neo-resistant clones derived from transfection of plasmid pITR(GFP-Neo)P5Rep. The conditions of
transfection and DNA analysis are described in Materials and Methods. (A) Hybridization to an AAVS1-specific probe. (B) Same member after
rehybridization to a neo probe. (Arrowhead) Upshifted bands that are annealed to both probes are considered to be indicative of site-specific
integrationn. Positions of molecular weight standards (in kb) are indicated.
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and replication assays (data not shown). Thus, the lack
of correlation in the hybridization pattern of the rep probe
with the neo and AAVS1 probes suggests that no inser-
tion of the DNA sequences located outside of the ITRs
has occurred into the AAVS1 site.
The site-specific integration of AAV genome into chro-
mosome 19 has mostly been mapped within the first 1.5
kb of the AAVS1 site (Kotin et al., 1992). To determine
whether in the Huh-7 cells transfected with the AAV-
derived plasmids integration had occurred in the same
region of AAVS1 as observed in AAV-infected cells, the
DNA from a transfected clone was analyzed using two
sets of nested primers that span the potential junction
between the ITR and chromosome 19 sequences (Good-
man et al., 1994). As a comparison, the DNA from AAV-
infected Huh-7 cells was subjected to the same PCR
amplification. These cells were infected with AAV at an
m.o.i. of 20 and passaged nine times before DNA extrac-
tion. The amplification products were identified as the
junction fragments by virtue of their hybridization to
AAVS1- and ITR-specific probes (data not shown) and
thus were cloned and sequenced. As shown in Figure 4,
the junction fragment derived from clone H6, which was
selected from cells transfected with plasmid pITR(GFP-
Neo)P5Rep, indicated that the insertion of the transfected
ITR-flanked DNA had occurred at nucleotide 1003 of
AAVS1 and that a deletion of 92 nucleotides of the ITR
had taken place. In addition, an insertion of 9 nucleotides
was detected at the ITR–AAVS1 crossover. Similarly, the
insertion of viral DNA was mapped at nucleotides 870,
1091, and 1116 of AAVS1 with a concomitant partial de-
letion of the ITR sequence of 61, 60, and 66 nucleotides,
respectively (Fig. 4, samples AAV/3, AAV/12, and AAV/26).
In one of the viral–cellular junction analyzed, a short 2-bp
homology was found at the crossover. Also, in two other
AAV–AAVS1 junctions, an insertion of 3 or 12 nucleotides
was detected at the viral–cellular crossover.
Taken together, these data indicate that integration of
the transfected plasmid DNA into the AAVS1 site occurs
with significant efficiency in different cell types and is
dependent on the presence of the rep gene. Further-
more, in agreement with published observations (Lamar-
tina et al., 1998; Shelling and Smith, 1994; Surosky et al.,
1997), targeted integration of the ITR-flanked DNA does
not require the expression of Rep52 and Rep40. Last, in
analogy to what has been observed on AAV infection of
cultured cell lines (Giraud et al., 1994; Kotin et al., 1990,
1992; Samulski et al., 1991), the transfected plasmid DNA
has integrated in the same region of the AAVS1 site.
In situ chromosome analysis of neomycin-resistant
HeLa cell clones
The site-specific integration of the AAV-derived plas-
mid was confirmed by fluorescent in situ hybridization
TABLE 1
Site-Specific Integration in Transfected and Selected Cell Clones
Plasmid
AAVS1-targeted
integration in
HeLa clonesa
AAVS1-targeted
integration in
Huh-7 clonesa
pITR(GFP-Neo) 0/39 (0%) ND
pITR(GFP-Neo)P5Rep 8/32 (25%) 3/29 (12%)
pITR(GFP-Neo)P5Rep78/68 7/68 (18%) 2/26 (7%)
Note. Integration into the AAVS1 site was assessed by DNA hybrid-
ization analysis with AAVS1- and neo-specific probes as described in
the text. ND, not determined.
a Number in parentheses indicates the efficiency of site-specific
integration.
FIG. 4. Analysis of PCR-amplified ITR–chromosome 19 junctions. Genomic DNA from Huh-7 cells infected with AAV virus and from the transfected
stable cell line H6 was subjected to PCR amplification using AAVS1- and ITR-specific primers. Clone H-6 was selected from Huh-7 cells transfected
with plasmid pITR(GFP-Neo)P5Rep. Amplified DNA was cloned, and the sequence of the H6 ITR–AAVS1 crossover was compared with three different
clones derived from the AAV-infected cells (AAV/3, AAV/12, and AAV/26) (Left) Part of the ITR-derived sequence. (Right) The cellular sequence.
(Underlining) DNA overlap between ITR and AAVS1 sequence. (Top numbers) Nucleotide position on the last identifiable viral and AAVS1 sequence.
(Lowercase letters) Amplified sequences that cannot be directly associated to either the ITR or the AAVS1.
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(FISH) analysis of cytogenetically prepared HeLa cell
chromosomes derived from HeLa cell clones, where
targeted integration into the AAVS1 site had been dem-
onstrated by Southern blot analysis (data not shown). For
this purpose, two probes were used: a 3.5-kb DNA frag-
ment corresponding to the entire GFP-Neo sequence
and a 80-kb DNA fragment isolated by screening of a
genomic DNA library using the 3.5-kb DNA fragment of
AAVS1 as a probe. Figure 5 demonstrates the presence
of the GFP-Neo sequence on each sister chromatid of a
single chromosome of HeLa cell clone P5–12 that had
been transfected with pITR(GFP-Neo)P5Rep. In addition,
the same region of the chromosome was hybridized by
the AAVS1-specific probe. Three other chromosomes
present in this HeLa cell clone annealed to the AAVS1-
specific probe, which is in agreement with the polyploid
nature of this cell line. However, no GFP-Neo sequence
could be detected, thus indicating that integration had
occurred only in one of the available AAVS1 sites. A
similar chromosomal staining was observed with two
other cell clones, whereas no GFP-Neo hybridization
was detected with mock-transfected cells (data not
shown). Thus, the data from the FISH analysis provide
further evidence for the targeted insertion of the AAV-
derived plasmid into the AAVS1 site of transfected cells.
DISCUSSION
In this study, we examined whether the rep gene of
AAV can direct the site-specific integration of a trans-
gene flanked by the ITRs of AAV. The results obtained
indicate that the targeted integration of a specific DNA
fragment to human chromosome 19 occurs at a signifi-
cant frequency and in different cell types.
The strategy devised in the construction of the plas-
mids used for the transfection experiments is based on
the assumption that the rep gene is required for site-
specific integration and that by inserting the Rep coding
sequences outside of the ITRs, the integration event is
limited to the gene of interest flanked by the AAV terminal
repeats. In addition, because the rep gene is not ex-
pected to be cointegrated with the ITR-flanked DNA, the
Rep coding sequence should be lost with time. Thus, the
transient nature of the Rep coding sequence may con-
tribute to the stability of the inserted DNA fragment by
limiting the possibility of further recombination events.
FIG. 5. FISH of GFP-Neo sequences in transfected HeLa cell clone. Chromosome preparation was hybridized with GFP-Neo- or AAVS1-specific
probes as described in Materials and Methods. (White arrow) Colocalization of the AAVS1-specific probe (red) and of the GFP-Neo-specific probe
(yellow).
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Our hypothesis is based on the observation that the
ITRs function as signals for the initiation of viral replica-
tion and for integration (Snyder et al., 1990; Urcelay et al.,
1995) and that the events leading to integration may
involve selective amplification of the ITR-flanked DNA
mediated by the Rep polypeptides (Linden et al., 1996).
The excision and replication of the ITR-flanked DNA can
be observed on transfection of plasmids containing the
AAV terminal sequences in Ad-infected cells as a func-
tion of Rep expression, in analogy to what is observed on
transfection of plasmid pSub201 (Fig. 2) (Samulski et al.,
1987). Last, in the selected HeLa and Huh-7 cell clones,
integration into the AAVS1 site of the transfected plasmid
is limited, at least in most cases, to the ITR-flanked DNA
sequence; this observation suggests that a mechanism
of selective excision and replication is likely to occur
before site-specific integration into chromosome 19 (data
not shown; Balague´ et al., 1997).
The results obtained on transfection of HeLa cells
indicate that insertion into the AAVS1 site is dependent
on the expression of the Rep polypeptides because no
site-specific integration is observed on transfection of
plasmid pITR(GFP-Neo) (Table 1). Thus, our results are in
agreement with the role of the Rep polypeptides in de-
termining the insertion of the AAV genome into the
AAVS1 site (Balague´ et al., 1997; Linden et al., 1996;
Shelling and Smith, 1994; Surosky et al., 1997). In addi-
tion, these results support the observation based on
FISH analysis of infected cells that current AAV vectors
lacking the rep gene will integrate into chromosome 19
only on coinfection with wild-type AAV, thus indicating
that expression of Rep proteins in trans-targeted integra-
tion in AAVS1 does occur (Ponnazhagan et al., 1997).
Interestingly, in latently infected cell lines, the AAV inser-
tion points have been located at AAVS1 nucleotides
1026–1030 and 1144–1146 (Kotin et al., 1992), in a region
of nucleotides 713–1303 (Samulski et al., 1991), and at
position 727 (Goodman et al., 1994). Infection of Huh-7
cells with AAV virus results in the insertion of the viral
DNA into the same general area of AAVS1. Similarly, the
junction fragment derived from PCR amplification of the
genomic DNA of the Huh-7 cell clone H6 transfected with
plasmid pITR(GFP-Neo)P5Rep indicates that the insertion
of the ITR-flanked DNA has occurred in the same region
of chromosome 19 (Fig. 4). The detection of a partial
deletion of the ITRs and of the insertion of a short stretch
of nucleotides between the ITR-cellular junction is not
unprecedented (Leonard and Berns, 1994; Kotin and
Berns, 1989; Palombo et al., 1998; Samulski et al., 1991;
Yang et al., 1997), and it may be a consequence of the
limited replication and rearrangement associated to Rep-
mediated integration.
The localization of the ITR-flanked DNA fragment
within the 59-end region of AAVS1 is also corroborated by
Southern blot analysis of all of the HeLa and Huh-7
clones with a genomic probe specific for nucleotides
1–1600. In these clones, the upshifted AAVS1 band was
detected with the 59-end probe of AAVS1, thus indicating
that the insertion of the ITR integration cassette had
occurred within this region (data not shown). Therefore,
the mechanism involved in the integration of the trans-
fected DNA is likely to be very similar to that responsible
for the insertion of the wild-type AAV genome into the
same region of chromosome 19.
An important requirement of the gene transfer strategy
outlined above is that the integration of the ITR-flanked
DNA into AAVS1 is not accompanied by rearrangements
of the inserted DNA that could render it nonfunctional.
With a significant frequency, transfection of plasmid
pITR(GFP-Neo)P5Rep in both HeLa and Huh-7 cells re-
sults in the single integration of the ITR-GFP-Neo DNA
fragment into the AAVS1 site, as shown by the Southern
blot analysis of the genomic DNA of selected clones.
This conclusion also is supported by FISH analysis of
HeLa cell clones that showed the presence of the GFP-
Neo sequence colocalized with the AAVS1 site and no
other metaphase chromosome (Fig. 5). Nevertheless, the
size of the upshifted bands indicative of site-specific
integration varies from one clone to the other and does
not match the sum of the size of the ITR-flanked DNA and
of the AAVS1 BamHI restriction fragment (;7 kb) (Fig. 3).
In addition, sequence analysis of the ITR–AAVS1 junction
of both infected and transfected Huh-7 cells revealed
that partial deletion of the AAV terminal repeat has taken
place on integration (Fig. 4). Thus, partial deletion or
rearrangement of both the inserted DNA and the AAVS1
site probably have occurred on integration. Neverthe-
less, although we cannot provide any evidence on GFP
expression simply because the gene used in this con-
struct is not functional (data not shown), the hybridization
data suggest that it is conceivable to obtain site-specific
integration of multiple functional genes, which can be
readily expressed after integration. In support of this
hypothesis, we recently observed that transduced 293
cells that carry a 6-kb DNA fragment consisting of the
hygromycin resistance as well as the b-galactosidase
gene integrated into the AAVS1 site are indeed resistant
to hygromycin and express significant amounts of b-ga-
lactosidase (Palombo et al., 1998).
Targeted integration of AAV-derived plasmids has
been described by Balague´ et al. (1997), who reported
that transfection of 293 cells with a construct expressing
Rep78 and Rep52 results in the site-specific integration
of a GFP gene flanked by the AAV ITRs in 50% of the
clones sorted on the basis of GFP expression. Interest-
ingly, the authors did not obtain the same result when
they used the neomycin resistance gene as a selectable
marker. By Southern blot analysis, they observed exten-
sive rearrangement of the AAVS1 locus associated with
the transfection of Rep-positive plasmid, which, however,
could not be ascribed to insertion of the neo gene. The
authors conclude that the lack of correspondence be-
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tween the neo and AAVS1 bands is an effect secondary
to the selective pressure applied. This conclusion, how-
ever, seems to be limited only to the 293 cells because
as stated above, we have not observed such rearrange-
ments in most of the transfected HeLa and Huh-7 clones
selected with neo. However, in view of the fact that
resistance to neomycin was used as selective pressure
for the isolation of transfected clones, it is possible that
the efficiency of integration detected in transfected HeLa
and Huh-7 cells is actually an underestimate of the real
efficiency of site-specific insertion in these cell lines. The
biological significance of these different experimental
results is not clear. However, taken together, these data
suggest that the overall ability of AAV to determine site-
specific integration into AAVS1 may be affected by dif-
ferences among human aneuploid cell lines. Such differ-
ences may be related to the concentration of host factors
present in the cell required for integration and to the level
of Rep expression obtained in each cell line. In particular,
the constitutive expression of E1A in 293 cells could
determine an higher level of expression from the P5
promoter, and this could, at least in part, influence the
efficiency of site-specific integration detected in this cell
line. Thus, it would be of interest to determine whether
the use of strong constitutive promoters for the expres-
sion of the Rep gene may affect the overall targeting
efficiency to the AAVS1 locus in E1A-negative cell lines.
The integration of therapeutic genes into specific lo-
cations of the DNA of nondividing cells accompanied by
prolonged expression is the optimal strategy for somatic
gene therapy. The results presented in this work indicate
that it is possible to devise a strategy aimed at the
insertion of specific DNA sequences at a predetermined
location of the human chromosomes. However, the func-
tionality of AAV-derived constructs must be properly ad-
dressed in a variety of different cell types and in primary
cultures in particular. Furthermore, the relevance of site-
specific integration in the in vivo persistence and expres-
sion of therapeutic genes await the development of suit-
able animal models in which AAV DNA insertion into the
AAVS1 site can be examined.
MATERIALS AND METHODS
Construction of recombinant plasmids
For pITR(GFP-Neo), pSub201 (Samulski et al., 1987)
was cut with XbaI to remove the Rep and Cap coding
sequences of AAV, and the 4.0-kb DNA fragment contain-
ing the ITR of AAV then was ligated to a 1.7-kb DNA
fragment carrying an NheI restriction site at either end.
This fragment contains the cDNA of the GFP (Chalfie et
al., 1994) flanked at its 59-end by the CMV immediate
early promoter and enhancer and by the bovine growth
hormone (bgh) polyadenylation signal at its 39-end. The
GFP fragment was obtained by PCR amplification with
sequence-specific primers using as template a deriva-
tive of vector pCDNA-3 (InVitrogen) in which the GFP
cDNA had been cloned [pCD3(GFP)]. The primer specific
for the bgh polyadenylation signal was designed so it
contains an SacII site located near the NheI site at the
39-end. The construct so obtained was named pITR-
(GFP). Plasmid pITR(GFP-Neo) was produced by insert-
ing the blunted EcoRI–BamHI fragment from pRc/RSV
(InVitrogen), which contains the SV40 early promoter,
neomycin resistance gene, and SV40 polyadenylation
signal, into the blunted SacII site of pITR(GFP).
pITR(GFP-Neo)P5Rep was derived from PCR amplifica-
tion of nucleotides 138–2234 of the AAV genome with
sequence-specific primers using plasmid pTAV-2 (Hei-
lbronn et al., 1990) as template. The amplified DNA frag-
ment was digested with ClaI and cloned into the ClaI site
of plasmid pITR(GFP-Neo).
pITR(GFP-Neo)P5Rep78/68 was constructed by insert-
ing into the ClaI site of plasmid pITR(GFP-Neo) a DNA
fragment extending from nucleotides 138–2234 of the
AAV genome in which the internal ATG for Rep52 and
Rep40 (nucleotides 993–995) had been changed to GGA.
The expression of the rep gene in plasmids pITR(GFP-
Neo)P5Rep and pITR(GFP-Neo)P5Rep78/68 was deter-
mined by Western blot analysis of Ad5-infected 293 cell
lysate that had been transfected with these constructs.
The expression of Rep78 and Rep68 was found to be
comparable to the level of Rep polypeptides expression
detected on transfection of the original construct
pSub201 (Samulski et al., 1987), which carries the full-
length genome of AAV, whereas no expression of Rep52
and Rep40 could be detected in cells transfected with
plasmid pITR(GFP-Neo)P5Rep78/68.
The replication capacity of the constructed plasmids
was assessed by transfecting 5 mg of plasmid DNA onto
293 cell monolayers that had been infected 1 h before
transfection with wild-type Ad2 at an m.o.i. of 10. Low-
molecular-weight DNA was isolated according to pub-
lished protocols (Hirt, 1967) from the cultures at 40 h after
transfection/infection, digested with restriction enzyme
DpnI for 4 h at 37°C, and analyzed by Southern blot
analysis using a probe specific for the ITR sequence.
Cell transfections
The 293, Huh-7, and HeLa cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum (FCS), 2 mM glutamine,
100 units/ml penicillin, and 100 mg/ml streptomycin. Cells
were grown in 10-cm dishes (Falcon) at 37°C in 5% CO2.
Stock cells were routinely passaged every 3 days by
treatment with trypsin (0.05%) and EDTA (0.53 mM) and
replated at cell densities appropriate for exponential
growth.
The 293 and HeLa cells were transfected according to
the calcium phosphate precipitate method using the cal-
cium phosphate mammalian cell transfection kit (5
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Prime-3 Prime) according to the manufacturer’s instruc-
tions. Twenty micrograms of plasmid DNA (10 mg of the
indicated plasmid plus 10 mg of carrier DNA) were trans-
fected in 1 3 106 cells. Sixteen hours after transfection,
the medium was replaced, and the cells were incubated
for an additional 32 h.
Transfection of the hepatoma cell line Huh-7 was per-
formed by using Lipofectin according to the manufactur-
er’s instructions (GIBCO BRL). The cell monolayer was
incubated in the presence of the DNA–Lipofectin mix for
12 h, the medium was replaced, and the cells were
incubated for an additional 32 h.
To isolate stable cell clones, the transfected cells were
then treated with trypsin and EDTA, and the cell suspen-
sion derived from a single 10-cm plate was diluted 1:3 in
selection medium (20 ml DMEM, 10% FCS, and 500
mg/ml G418) and plated onto three 15-cm plates (Falcon).
Neomycin-resistant clones were isolated after 10 days of
selection, expanded, and processed for genomic DNA
extraction, Southern blot, and FISH analyses.
Southern blot analysis of transfected clones
Cell clones resistant to neomycin were grown in 10-cm
plates, and the cell monolayer was detached by scraping
and washed twice with 2 ml of PBS. The cell suspension
was transferred to Eppendorf tubes, and the cells were
pelleted and resuspended in 0.5 ml of TEN (50 mM
Tris–Cl, pH 7.5, 150 mM NaCl, 10 mM EDTA). SDS and
Proteinase K were added to each sample to final con-
centrations of 1% and 1 mg/ml, respectively. The cell
lysate was incubated for 4 h at 56°C and subjected to
three consecutive extractions with phenol (equilibrated
with 10 mM Tris–Cl, pH 8.0, 1 mM EDTA), phenol and
chloroform (1:1 ratio), and chloroform. The DNA was
precipitated in ethanol, resuspended in 0.5 ml of H2O,
and incubated overnight at 4°C. Ten micrograms of high-
molecular-weight chromosomal DNA were incubated
with 40 units of the restriction enzyme BamHI (New
England Biolabs) in a 0.1-ml volume for 12 h at 37°C. The
digested DNA was electrophoresed on a 0.8% agarose
gel, transferred to nylon membrane (Hybond N1; Amer-
sham) as recommended by the manufacturer, and hy-
bridized overnight at 65°C in Church buffer (7% SDS, 0.25
M NaPi, pH 7.2, 1 mM EDTA, pH 8.0, 0.1 g/ml bovine
serum albumin) with random-primed 32P-labeled probes.
Filters were washed in 40 mM NaPi, pH 7.2, 1 mM EDTA,
pH 8.0, and 1% SDS at 65°C three times for 20 min and
then in 0.13 SSC and 0.1% SDS at 65°C for 20 min. Filters
were exposed to x-ray film with an intensifying screen for
1 week. To determine site-specific integration of the ITR
DNA fragment, filters were first hybridized with a probe
specific for the neomycin gene, the hybridized probe
then was removed by boiling the filters in 0.23 SSC and
1% SDS for 10 min, and the same filters then were
hybridized to a probe specific for the AAVS1 site. The
probe specific for the chromosome 19 was obtained by
random priming reaction using as template a DNA frag-
ment derived from plasmid pRVK (K. Berns, Cornell Med-
ical School, New York, New York) covering nucleotides
1–3525 of AAVS1 (Kotin et al., 1992). DNA fragments of
630 and 750 bp were used as templates in random-
priming reactions for the synthesis of neo- and GFP-
specific probes, respectively.
Huh-7 infection and PCR amplification of ITR–AAVS1
junction
Wild-type AAV-2 virus was prepared by transfection of
Ad5-infected 293 cells with plasmid pSub201 according
to published protocols (Samulski et al., 1982, 1987).
Semiconfluent Huh-7 cells were infected at an m.o.i. of
20 infectious units per cell. After absorption for 1 h at
37°C, the medium was replenished, and the cells were
incubated for 2 days until they reached confluence. Cells
were harvested and split 1:5 and incubated again at
37°C for several days. After nine passages, the presence
of AAV virus in the cell culture was confirmed by per-
forming a rescue and replication assay (Samulski et al.,
1982), the cells were harvested, and genomic DNA was
extracted. Integration of AAV-2 viral genome was com-
pared with that of transfected ITR-flanked DNA fragment
by PCR using nested primer pairs that flank the AAV–
chromosome junction as previously described (Good-
man et al., 1994): primers 16s (AAV) 59-GTAGCATGGCG-
GGTTAATCA and 15a (AAVS1) 59-GCGCGCATAAGCCAG-
TAGAGC were used in the first round of PCR amplifica-
tion with 0.5 mg of genomic DNA as substrate. After an
initial incubation for 4 min at 94°C, the reaction mixture
was subjected to 30 cycles of PCR amplification with
following parameters: 1 min at 94°C, 1 min at 55°C,and
2 min at 72°C. Twenty percent of the amplification prod-
uct was diluted into a new reaction mixture containing a
set of nested primers with the following sequences: 17s
(AAV) (59-TTAACTACAAGGAACCCCTA) and Cr2 (AAVS1)
(59-ACAATGGCCAGGGCCAGGCAG). The PCR parame-
ters were the same as for the first amplification. The
products were resolved on a 1% agarose gel, transferred
to Hybond N1 paper (Amersham), and probed with ITR
(nucleotides 4563–4670) and AAVS1 (nucleotides 210–
1207) restriction fragments labeled by Amersham Mega-
prime DNA labeling system. For molecular cloning of the
amplified junction fragments, the product of the second
round of amplification was purified on a 1% agarose gel
and subcloned by blunt-end ligation into plasmid pZERO-
2.1 (InVitrogen). Sequencing was performed using stan-
dard chain termination protocols.
In situ hybridization
A 3.5-kb DNA fragment corresponding to the entire
GFP-Neo sequence and an 80-kb AAVS1 DNA isolated
by screening a genomic DNA library were labeled using
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the Nick Translation Kit (Boehringer-Mannheim) accord-
ing to the manufacturer’s instructions and used as
probes in chromosome analysis.
The chromosome spreads from selected clones were
prepared according to typical cytogenetic techniques
(Lawrence et al., 1988). Cytogenetic preparations were
pretreated with 0.05% pepsin solution and dehydrated
through cold 70%, 90%, and 100% ethanol. The prepara-
tions then were denatured using a 70% formamide solu-
tion. Hybridization conditions were as previously de-
scribed (Palombo et al., 1998). Visualization of the biotin-
labeled probe was carried out by repeated incubations
with Cy3-avidin (Amersham), biotinylated anti-avidin D
(Vector Laboratories), and Cy3-avidin. The digoxigenin-
labeled probe was detected using mouse anti-digoxige-
nin, digoxigenin-labeled anti-mouse, and FITC-labeled
anti-digoxigenin antibodies (Boehringer-Mannheim). Al-
ternatively, FITC-avidin (Vector Laboratories) and rho-
damine-labeled anti-digoxigenin (Boehringer-Mannheim)
antibodies were used. After immunodetection, slides
were counterstained with 200 ng/ml 49,69-diamidino-2-
phenylindole. UV excitation was used to locate met-
aphases, and photographic images were taken with a
CCD camera (Photometrics) using green (FITC signal) or
blue violet (Cy3 or rhodamine) illumination. Images were
processed using Adobe Photoshop on an Apple Quadra
computer.
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